Ahn-Gook Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Ahn-Gook Pharmaceutical's earnings have been declining at an average annual rate of -8.1%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 6.8% per year. Ahn-Gook Pharmaceutical's return on equity is 0.7%, and it has net margins of 0.6%.
Key information
-8.1%
Earnings growth rate
-7.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 6.8% |
| Return on equity | 0.7% |
| Net Margin | 0.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Are Dividend Investors Making A Mistake With Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?
Apr 02
Ahn-Gook Pharmaceutical (KOSDAQ:001540) Shareholders Booked A 29% Gain In The Last Year
Mar 07Is Ahn-Gook Pharmaceutical (KOSDAQ:001540) Using Too Much Debt?
Feb 14Do Insiders Own Lots Of Shares In Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)?
Jan 19Dividend Investors: Don't Be Too Quick To Buy Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Upcoming Dividend
Dec 24A Look At The Fair Value Of Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)
Dec 10Key Things To Consider Before Buying Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540) For Its Dividend
Nov 18
Revenue & Expenses BreakdownBeta
How Ahn-Gook Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 233,676 | 1,290 | 122,101 | 12,255 |
| 30 Sep 23 | 226,186 | 4,581 | 118,675 | 13,045 |
| 30 Jun 23 | 224,219 | 7,801 | 113,498 | 13,290 |
| 31 Mar 23 | 213,414 | 8,298 | 106,305 | 13,384 |
| 31 Dec 22 | 205,389 | 6,875 | 102,477 | 12,957 |
| 30 Sep 22 | 195,740 | 9,471 | 100,579 | 12,613 |
| 30 Jun 22 | 182,760 | 7,005 | 94,842 | 13,243 |
| 31 Mar 22 | 175,163 | 4,077 | 91,384 | 15,523 |
| 31 Dec 21 | 163,534 | 3,939 | 83,329 | 17,328 |
| 30 Sep 21 | 149,137 | 1,391 | 72,662 | 17,768 |
| 30 Jun 21 | 143,734 | 242 | 70,046 | 17,789 |
| 31 Mar 21 | 141,126 | -2,505 | 65,993 | 17,405 |
| 31 Dec 20 | 143,364 | -1,315 | 66,046 | 16,993 |
| 30 Sep 20 | 156,318 | -1,003 | 68,856 | 28,013 |
| 30 Jun 20 | 160,059 | 215 | 69,729 | 23,942 |
| 31 Mar 20 | 158,870 | 3,339 | 72,862 | 16,351 |
| 31 Dec 19 | 155,852 | 2,536 | 74,161 | 15,583 |
| 30 Sep 19 | 167,392 | 7,416 | 75,407 | 26 |
| 30 Jun 19 | 173,064 | 8,524 | 77,360 | 41 |
| 31 Mar 19 | 179,166 | 12,862 | 77,041 | 3,058 |
| 31 Dec 18 | 185,746 | 13,220 | 81,141 | 77 |
| 30 Sep 18 | 177,663 | 7,111 | 84,410 | 71 |
| 30 Jun 18 | 177,601 | 8,641 | 82,710 | 71 |
| 31 Mar 18 | 179,556 | 8,209 | 83,908 | 66 |
| 31 Dec 17 | 183,600 | 8,159 | 80,681 | 84 |
| 30 Sep 17 | 182,032 | 9,839 | 73,531 | 84 |
| 30 Jun 17 | 179,048 | 5,884 | 70,904 | 85 |
| 31 Mar 17 | 176,178 | 2,700 | 66,954 | 109 |
| 31 Dec 16 | 174,002 | 1,715 | 65,440 | 104 |
| 30 Sep 16 | 183,923 | -185 | 65,040 | 298 |
| 30 Jun 16 | 188,194 | 3,025 | 65,797 | 281 |
| 31 Mar 16 | 195,871 | 7,926 | 67,732 | 240 |
| 31 Dec 15 | 197,736 | 9,364 | 66,948 | 213 |
| 30 Sep 15 | 185,569 | 4,360 | 64,593 | 452 |
| 30 Jun 15 | 181,973 | 3,171 | 64,641 | 452 |
| 31 Mar 15 | 173,784 | 1,123 | 61,423 | 452 |
| 31 Dec 14 | 167,936 | -784 | 58,404 | 452 |
| 30 Sep 14 | 161,703 | 7,562 | 55,735 | 591 |
| 30 Jun 14 | 154,380 | 6,775 | 54,374 | 591 |
| 31 Mar 14 | 152,945 | 4,308 | 54,535 | 591 |
| 31 Dec 13 | 153,972 | 6,767 | 57,251 | 591 |
| 30 Sep 13 | 154,260 | 166 | 60,211 | 592 |
| 30 Jun 13 | 151,795 | -455 | 59,458 | 592 |
Quality Earnings: A001540 has a large one-off gain of ₩938.8M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: A001540's current net profit margins (0.6%) are lower than last year (3.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A001540's earnings have declined by 8.1% per year over the past 5 years.
Accelerating Growth: A001540's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A001540 had negative earnings growth (-81.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (36.1%).
Return on Equity
High ROE: A001540's Return on Equity (0.7%) is considered low.